-

Bristol Myers Squibb Announces Dividend

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2023, to stockholders of record at the close of business on July 7, 2023.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on September 1, 2023, to stockholders of record at the close of business on August 1, 2023.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Versions
English
$Cashtags
$BMY

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com

Social Media Profiles
Bristol Myers Squibb/Twitter
More News From Bristol Myers Squibb

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years...

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM...

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

PRINCETON, N.J.--(BUSINESS WIRE)--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy....
Back to Newsroom